Copyright © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Editor-in-Chief: Natalia Ortúzar
Impact Factor: 3.046
ISI Journal Citation Reports © Ranking: 2013: 18/58 (Chemistry Medicinal); 74/254 (Pharmacology & Pharmacy)
Online ISSN: 1860-7187
August 28, 2014
C. A. Olsen interview at ChemistryViews
ChemMedChem author and this year's recipient of the EFMC Prize for a Young Medicinal Chemist in Academia, Professor Christian A. Olsen (University of Copenhagen), recently answered some questions we had about the work behind his paper Effect of Various Zinc Binding Groups on Inhibition of Histone Deacetylases 1–11, which appeared earlier this year in our Special Issue on Epigenetics and Drug Discovery. He also discussed his research projects and goals in general, and what makes his successful research group tick. The full interview can be found at ChemistryViews. Be sure to catch Olsen's Concept article, also in the Epigenetics special issue.
Recently Published Articles
- Discovery of a Highly Selective PLD2 Inhibitor (ML395): A New Probe with Improved Physiochemical Properties and Broad-Spectrum Antiviral Activity against Influenza Strains
Matthew C. O'Reilly, Thomas H. Oguin III, Dr. Sarah A. Scott, Prof. Paul G. Thomas, Dr. Charles W. Locuson, Ryan D. Morrison, Prof. J. Scott Daniels, Prof. H. Alex Brown and Prof. Craig W. Lindsley
Article first published online: 10 SEP 2014 | DOI: 10.1002/cmdc.201402333
PLD2, viral killer! Focused optimization efforts led to the development of ML395, a potent (IC50=360 nM) and >80-fold selective phospholipase D2 (PLD2) inhibitor with improved physiochemical properties, no cytotoxicity, high CNS penetration and a favorable DMPK profile. The PLD2 inhibitors displayed pan-anti-influenza activity across various influenza strains (H1N1, H3N2, H5N1, H7N9).
- Comparative Cytotoxicity of Artemisinin and Cisplatin and Their Interactions with Chlorogenic Acids in MCF7 Breast Cancer Cells
Dr. John O. Suberu, Dr. Isolda Romero-Canelón, Dr. Neil Sulluvan, Prof. Alexei A. Lapkin and Dr. Guy C. Barker
Article first published online: 10 SEP 2014 | DOI: 10.1002/cmdc.201402285
Ironing out the infusion: Strong antagonistic interactions between artemisinin and chlorogenic acids in MCF7 cells has negative implications for the use of Artemisia tea in chemotherapy. It is possible that the chlorogenic acids present sap artemisinin of its potency by chelating cellular iron.
- Nucleoside Mono- and Diphosphate Prodrugs of 2′,3′-Dideoxyuridine and 2′,3′-Dideoxy-2′,3′-didehydrouridine
Dr. Florian Pertenbreiter, Prof. Dr. Jan Balzarini and Prof. Dr. Chris Meier
Article first published online: 10 SEP 2014 | DOI: 10.1002/cmdc.201402295
Chemical Trojan horses: Can they rescue antiviral activity? Nucleoside mono- and diphosphate prodrugs of d4U and ddU were prepared by applying the cycloSal and DiPPro approaches. These compounds underwent successful delivery, but surprisingly showed weak or no antiviral activity. Phosphorylation studies with nucleoside diphosphate kinase showed that this enzyme is practically unable to convert ddUDP and d4DUP to the triphosphate form.
- Discovery and Characterization of 2-(Cyclopropanesulfonamido)-N-(2-ethoxyphenyl)benzamide, ML382: a Potent and Selective Positive Allosteric Modulator of MrgX1
Wandong Wen, Dr. Yan Wang, Zhe Li, Dr. Pang-Yen Tseng, Dr. Owen B. McManus, Dr. Meng Wu, Dr. Min Li, Prof. Craig W. Lindsley, Prof. Xinzhong Dong and Prof. Corey R. Hopkins
Article first published online: 10 SEP 2014 | DOI: 10.1002/cmdc.201402277
PAM for MrgX1: A recently performed high-throughput screen identified a series of aryl sulfonamides as positive allosteric modulators (PAMs) for MrgX1. An iterative parallel medicinal chemistry effort and pharmacological profiling led to the discovery of a potent and selective MrgX1 PAM, ML382 (VU0485891) with sub-micromolar potency (EC50=190 nM).
- Modeling the Interaction between Dendrimers and Nucleic Acids: a Molecular Perspective through Hierarchical Scales
Dr. Giovanni M. Pavan
Article first published online: 10 SEP 2014 | DOI: 10.1002/cmdc.201402280
A privileged view: The binding between dendrimers and nucleic acids is typically a complex process that involves various types of interactions at different scales. Molecular simulation can support experimental data, providing a privileged point of view on intermolecular interactions and on the aggregation process.